CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY)

CHURCHILL MANAGEMENT Corp grew its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 178,922 shares of the biopharmaceutical company's stock after purchasing an additional 4,869 shares during the quarter. CHURCHILL MANAGEMENT Corp owned 0.09% of Incyte worth $12,358,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. CWA Asset Management Group LLC acquired a new stake in Incyte during the fourth quarter valued at approximately $1,933,000. Orion Portfolio Solutions LLC acquired a new stake in shares of Incyte during the 3rd quarter valued at $770,000. Greenwood Capital Associates LLC bought a new stake in shares of Incyte during the 3rd quarter worth $433,000. Tri Ri Asset Management Corp acquired a new position in shares of Incyte in the 3rd quarter worth $3,292,000. Finally, Cypress Capital Group acquired a new stake in shares of Incyte during the third quarter worth $971,000. Institutional investors own 96.97% of the company's stock.

Insiders Place Their Bets

In related news, EVP Vijay K. Iyengar sold 6,043 shares of Incyte stock in a transaction on Friday, November 29th. The shares were sold at an average price of $75.38, for a total value of $455,521.34. Following the transaction, the executive vice president now owns 30,658 shares in the company, valued at $2,311,000.04. This trade represents a 16.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Barry P. Flannelly sold 3,680 shares of the company's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $79.68, for a total transaction of $293,222.40. Following the sale, the executive vice president now owns 58,042 shares of the company's stock, valued at $4,624,786.56. This trade represents a 5.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,023 shares of company stock valued at $839,711 over the last quarter. Insiders own 17.60% of the company's stock.

Incyte Stock Up 0.0 %

NASDAQ INCY traded up $0.01 during trading on Thursday, reaching $72.47. The company's stock had a trading volume of 1,099,995 shares, compared to its average volume of 1,540,569. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $13.96 billion, a PE ratio of 517.68, a PEG ratio of 0.51 and a beta of 0.71. The business has a 50-day moving average price of $72.78 and a 200-day moving average price of $67.81. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.12). The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The firm's revenue for the quarter was up 23.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.91 EPS. On average, research analysts forecast that Incyte Co. will post 0.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on INCY. Wolfe Research started coverage on Incyte in a research report on Tuesday, October 1st. They issued an "outperform" rating and a $84.00 price target for the company. Citigroup raised their target price on shares of Incyte from $92.00 to $97.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company boosted their price target on shares of Incyte from $68.00 to $70.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. Oppenheimer upped their price target on shares of Incyte from $81.00 to $82.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Finally, BMO Capital Markets reiterated an "underperform" rating and set a $52.00 price objective (up from $48.00) on shares of Incyte in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $76.29.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.